This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, T. W. Articles by Wu, T-C. Search for Related Content PubMed PubMed Citation Articles by Kim, T. W. Articles by Wu, T-C.

Modification of Professional Antigen-Presenting Cells with Small Interfering RNA In vivo to Enhance Cancer Vaccine Potency

Departments of ¹ Pathology, ² Obstetrics and Gynecology, ³ Oncology, ⁴ Pharmacology and Molecular Sciences, ⁵ Neurology, and ⁶ Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, Maryland and ⁷ Department of Advanced Materials, Korea Research Institute of Chemical Technology, Daejon, Korea

Requests for reprints: T-C. Wu, Department of Pathology, Johns Hopkins University School of Medicine, Ross 512H, 720 Rutland Avenue, Baltimore, MD 21205. Phone: 410-614-3899; Fax: 443-287-4295; E-mail: wutc{at}jhmi.edu.

RNA interference using small interfering RNA (siRNA) is an effective means of silencing gene expression in cells. Intradermal administration of nucleic acids via gene gun represents an efficient method for delivering nucleic acids to professional antigen-presenting cells in vivo. In this study, we show that the coadministration of DNA vaccines encoding human papillomavirus type 16 E7 with siRNA targeting key proapoptotic proteins Bak and Bax prolongs the lives of antigen-expressing dendritic cells in the draining lymph nodes, enhances antigen-specific CD8⁺ T-cell responses, and elicits potent antitumor effects against an E7-expressing tumor model in vaccinated mice. Our data indicate that intradermal administration of siRNA to manipulate gene expression represents a plausible strategy for modification of the properties of professional antigen-presenting cells in vivo to enhance cancer vaccine potency.

Key Words: Cancer vaccine • Dendritic cell • Immunotherapy • siRNA • DNA vaccine

This article has been cited by other articles:

				T. Wang, Q. Jiang, C. Chan, K. S. Gorski, E. McCadden, D. Kardian, D. Pardoll, and K. A. Whartenby Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR Blood, March 26, 2009; 113(13): 2906 - 2913. [Abstract] [Full Text] [PDF]

				R. S. Kornbluth and G. W. Stone Immunostimulatory combinations: designing the next generation of vaccine adjuvants J. Leukoc. Biol., November 1, 2006; 80(5): 1084 - 1102. [Abstract] [Full Text] [PDF]

				L. Shi, K. Luo, D. Xia, T. Chen, G. Chen, Y. Jiang, N. Li, and X. Cao DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses Blood, October 15, 2006; 108(8): 2678 - 2686. [Abstract] [Full Text] [PDF]

				O. Shefi, C. Simonnet, M. W. Baker, J. R. Glass, E. R. Macagno, and A. Groisman Microtargeted gene silencing and ectopic expression in live embryos using biolistic delivery with a pneumatic capillary gun. J. Neurosci., June 7, 2006; 26(23): 6119 - 6123. [Full Text] [PDF]

				J. J. Donnelly, B. Wahren, and M. A. Liu DNA Vaccines: Progress and Challenges J. Immunol., July 15, 2005; 175(2): 633 - 639. [Abstract] [Full Text] [PDF]